Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
Marcos Gamboa Chele, Internal Medicine Specialist, shared a post on LinkedIn about a recent article by Jiwon Shin et al, adding:
”Are we asking for too many thrombophilia panels?
Venous thromboembolism (VTE) affects 1 in 1,000 people worldwide each year. However, the current clinical evidence is clear: universal or routine screening for thrombophilia in all patients with VTE is not recommended.
Based on the recent review ‘Selective Thrombophilia Testing in Venous Thromboembolism’, here is a practical summary of its benefits, limitations, and how to apply it in our daily practice.
Benefits of Selective Testing
In carefully selected patients (unprovoked VTE, younger than 50 years, thrombosis at unusual sites, or strong family history), evaluation offers valuable information for individualized management and prevention of recurrences.
The identification of high-risk conditions, such as Antiphospholipid Syndrome (APS) or Antithrombin deficiency, may alter the choice or duration of anticoagulation, justifying indefinite therapies.
It allows for structured genetic and family counseling when serious hereditary defects are confirmed.
Limitations and Challenges
False positives and negatives: Functional assays are highly sensitive to acute phase reaction and the use of direct oral anticoagulants (DOACs), which can lead to misleading results.
Ethnic variation: Factor V Leiden and Prothrombin G20210A mutations are common in Western populations, but extremely rare in Asians. In contrast, deficiencies of natural anticoagulants are more significant in the latter populations.
Marginal clinical impact: Discovering a mild hereditary defect rarely alters the management of anticoagulation and has not been shown to improve mortality.
Practical Applicability in the Flat or Consultation
Zero tests in provoked VTE: If the event was triggered by surgery, trauma, or estrogen use, the test has limited diagnostic and therapeutic value.
Time is money: Testing for Protein C, Protein S, and Antithrombin should be postponed until the patient is recovered and 2-6 weeks after stopping blood-thinning therapy.
Lean on genetics: Unlike functional testing, genetic (DNA) testing for specific mutations can be performed at any time, as they are not affected by blood thinners or acute illness.”
Title: Selective Thrombophilia Testing in Venous Thromboembolism
Authors: Jiwon Shin, Hyejee Lee, Hyangkyoung Kim
Read the Full Article on Annals of Phlebology
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation